Cilostazol Reduces Target Lesion Revascularization After Percutaneous Transluminal Angioplasty in the Femoropopliteal Artery

Iida, Osamu; Nanto, Shinsuke; Uematsu, Masaaki; Morozumi, Takakazu; Kotani, Jun–ichi; Awata, Masaki; Onishi, Toshinari; Ito, Noriaki; Oshima, Fusako; Minamiguchi, Hitoshi; Kitakaze, Masafumi; Nagata, Seiki

doi:10.1253/circj.69.1256

Cited by 36 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, some randomized control trials have shown that cilostazol improved long-term results in SFA intervention. [17][18][19] In the present trial, cilostazol was identified as an independent factor associated with primary patency.…”

Section: Discussionmentioning

confidence: 55%

Long-Term Results of the S.M.A.R.T. ControlTM Stent for Superficial Femoral Artery Lesions, J-SMART Registry

Suzuki

Iida

Soga

et al. 2011

Circ J

Self Cite

View full text Add to dashboard Cite

Background:The use of a stent in the treatment of lesions of the superficial femoral artery (SFA) remains controversial. Although some reports have suggested that use of a nitinol stent in conjunction with aggressive medical management is effective for long SFA lesions, few long-term, large-scale studies have been done. Methods and Results:A retrospective analysis was conducted of data from a multicenter study in which the S.M.A.R.T. Control™ stent was used for treatment of de novo SFA lesions. A total of 528 lesions in 432 patients were included. Mean patient age was 72.5±9.1 years; mean stent length was 15.7±8.1 cm; 259 lesions (49%) were classified as C/D according to the TransAtlantic Inter-Society Consensus (TASC) II classification. Primary and secondary patency at 4 years was 66% and 87%, respectively. No cilostazol administration (41% re-stenosis group vs. 29% no-restenosis group, P<0.01), female gender (42% vs. 26%, P<0.01), younger age (70.7±9.3 years vs. 72.9±9.0 years, P<0.05), and chronic total occlusion (CTO; 72% vs. 52%, P<0.01) were independent predictors of re-stenosis.Conclusions: The S.M.A.R.T. Control™ stent provided good long-term durability in the treatment of SFA lesions, and no cilostazol administration, female gender, younger age and CTO were associated with re-stenosis. (Circ J 2011; 75: 939 - 944)

show abstract

Section: Discussionmentioning

confidence: 55%

Long-Term Results of the S.M.A.R.T. ControlTM Stent for Superficial Femoral Artery Lesions, J-SMART Registry

Suzuki

Iida

Soga

et al. 2011

Circ J

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, chronic cilostazol treatment prevents TLR after PTA of the femoropopliteal artery in the general population (16). However, it is unclear whether this extends to high-risk individuals, such as those receiving HD.…”

mentioning

confidence: 99%

Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease

Ishii

Kumada

Toriyama

et al. 2008

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…The findings that lower limb severity was significantly associated with primary patency and that cilostazol reduced the restenosis rate after EVT 11 were compatible with previous observations. 1,2,11,12 Taken together, we can safely say that primary nitinol stenting is an attractive alternative to the angioplasty alone for TASC II A/B FPA lesions. Peripheral artery disease (PAD) has been estimated to affect more than 10 million in the United States 13,14 and also has been increasing in Asia.…”

Section: Discussionmentioning

confidence: 95%

Long-Term Results of Endovascular Therapy With Nitinol Stent Implantation for TASC II A/B Femoro-Popliteal Artery Lesions 4 Years' Experience

Iida

Nanto

Uematsu

et al. 2009

Circ J

Self Cite

View full text Add to dashboard Cite

lthough the initial success rate of endovascular therapy (EVT) for femoro-popliteal artery (FPA) had been reported as 95% for stenotic and more than 85% for occlusive lesions, 1 mid-and long-term patency has remained an unsolved clinical issue. [1][2][3] Balloon angioplasty, which is the conventional and traditional treatment for FPA lesions, is extremely limited because of its low primary patency rate of 40-60% after 6-12 months. 4,5 Early experience with stainless-steel stents showed no beneficial superiority of primary patency to angioplasty alone for FPA lesions, 6,7 so deployment of these stents was limited to cases of failed angioplasty in the TASC 2000 document. 2 Interestingly, in a retrospective study nitinol stents were associated with a significantly improved primary patency rate in FPA lesions compared with stainless steel stents, 8 and recently, treatment of superficial femoral artery (SFA) disease by primary implantation of a nitinol stent yielded results that were superior to those with the currently recommended approach of balloon angioplasty with optional secondary stenting at 12 months. 9 These improvements in primary patency contributed to a revision of the TASC II document. 1Although EVT with a nitinol stent is widely used in clinical practice for TASC II A/B lesions, the primary patency beyond 2 years remains unclear. Also, there are no clinical data regarding the predictors influencing the primary patency in the nitinol stent era. Therefore, in the present study we investigated the primary patency for as long as 4 years and sought the factors associated with patency after EVT with a nitinol stent in TASC II A/B FPA lesions. Methods Study SubjectsFrom April 2004 to December 2007, we retrospectively analyzed a prospectively maintained database that included 126 patients (189 limbs) who were successfully and consecutively treated with a nitinol stent for de novo TASC II A/B FPA lesions and who gave consent to undergo followup ultrasound and X-ray in the Cardiovascular Division of Kansai Rosai Hospital, Japan. All patients had symptoms of the FPA lesions (Rutherford 2-6) that affected their quality of life despite exercise and medication. We developed the study protocol in accordance with the Declaration

show abstract

Cilostazol Reduces Target Lesion Revascularization After Percutaneous Transluminal Angioplasty in the Femoropopliteal Artery

Cited by 36 publications

References 34 publications

Long-Term Results of the S.M.A.R.T. ControlTM Stent for Superficial Femoral Artery Lesions, J-SMART Registry

Long-Term Results of the S.M.A.R.T. ControlTM Stent for Superficial Femoral Artery Lesions, J-SMART Registry

Cilostazol Improves Long-Term Patency after Percutaneous Transluminal Angioplasty in Hemodialysis Patients with Peripheral Artery Disease

Long-Term Results of Endovascular Therapy With Nitinol Stent Implantation for TASC II A/B Femoro-Popliteal Artery Lesions 4 Years' Experience

Contact Info

Product

Resources

About